Abstract
Materials and methods DCE-CT images of 33 patients, with recurrent/metastatic NPC treated with pazopanib, were analyzed to derive tumour blood flow, fractional intravascular blood volume, fractional extracellular-extravascular volume, and permeability surface area product. To each parametric map, textural analysis using multiple parameters based on co-occurrence matrix, neighbourhood gray tone difference, run-length matrix, gray level size-zone matrix and histogram statistics were applied to characterize its heterogeneity. Reproducible and important textures, were selected by a cut-off on the coefficient of variation and variable importance determined by random forest analysis, respectively. These textures are summarized by principal components analysis and their relationship to outcomes evaluated using Cox proportional hazards, receiver-operating characteristics, Kaplan-Meier and logistics regression analysis.
Highlights
This study aims to evaluate the impact of tumour vascular heterogeneity, derived from textural analysis of dynamic contrast-enhanced computed tomography (DCE-CT) perfusion characteristics in patients with NPC treated with the anti-angiogenic drug, pazopanib
Materials and methods DCE-CT images of 33 patients, with recurrent/metastatic NPC treated with pazopanib, were analyzed to derive tumour blood flow, fractional intravascular blood volume, fractional extracellular-extravascular volume, and permeability surface area product
Using Kaplan Meier analysis, overall survival was significantly higher for patients with PC1 values greater than the median (p=0.002)
Summary
Use of textural analysis of tumour vascular heterogeneity as a biomarker of response to anti-angiogenic treatment in patients with nasopharyngeal carcinoma Qiao Qi Teo1*, Benjamin Haaland1, Choon Hua Thng2, Wan Teck Lim3, Tong San Koh1,2, Quan-Sing Ng3 From International Cancer Imaging Society (ICIS) 14th Annual Teaching Course Heidelberg, Germany.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have